Use of alphavirus in preparation of antitumor drugs
AssigneeGuangzhou Virotech Pharmaceutical Co., Ltd.
InventorsGuangmei Yan, Xiao Xiao, Jun Hu, Kai Li, Jiankai Liang, Yuan Lin, Haipeng Zhang, Suizhen Lin
Life of this patent
Estimating the term…
Abstract
Disclosed is use of alphavirus in preparation of antitumor drugs. The alphavirus is M1 virus or Getah virus. In addition, the specific tumor types sensitive to abovementioned alphavirus treatment are further determined, so as to provide a safe and effective solution for antitumor drug administering schemes.
Claims45
A method of treating a human subject that has a tumor, comprising administering to the subject at least one alphavirus, wherein said at least one alphavirus is an M1 virus, and wherein the tumor is a ZAP low expression tumor or a ZAP negative tumor.
A method of treating a human subject that has a tumor, comprising administering to the subject at least one alphavirus, wherein said at least one alphavirus is an M1 virus, and wherein before administering, the subject is subjected to the detection of tumor ZAP expression level, and,
- a) if the tumor is of ZAP low expression or ZAP negative expression, said alphavirus is directly administered;
- b) if the tumor is of ZAP normal expression/ZAP high expression, a ZAP inhibitor is provided before or during the administration of the M1 virus.
A method of treating a human subject that has a tumor, comprising administering to the subject at least one alphavirus, wherein said at least one alphavirus is an M1 virus, and wherein the genome of said at least one alphavirus has at least 97.8% nucleotide sequence identity to the genome of the M1 virus deposited under Accession No. CCTCC V201423.
Dependencies are inferred from the claim text.